Listen as expert oncologists discuss the most important things to know about platinum-resistant ovarian cancer.
annual diagnosed cases in the US1
most common
gynecologic malignancy2
of patients pass away from
late-stage disease3
Ovarian cancer is diagnosed in stages III to IV in approximately 75% of cases4
Nonspecific symptoms common in ovarian cancer can be misattributed to other conditions or health issues.5
Defining platinum resistance
Ovarian cancer with a treatment-free interval of <6 months since the last
line of treatment with platinum chemotherapy7
~85% of patients experience recurrence and become platinum resistant7
Women diagnosed with ovarian cancer typically undergo surgery and platinum-based chemotherapy during frontline treatment.8
Despite recent advancements, women living with PROC face a challenging journey.11
become resistant to platinum chemotherapy7
median progression-free survival with current options12
median overall survival with current options13
for FDA-approved biomarker therapies11
Treatment options for platinum-resistant ovarian cancer have evolved in recent years, including the availability of newer therapies. Despite these advances, clinical outcomes remain challenging, and disease progression is commonly observed within a few months following single-agent chemotherapy.11,13-14
Treatment options for platinum-resistant ovarian cancer include single-agent chemotherapy, bevacizumab-containing regimens, biomarker-targeted therapies, and newer treatment approaches. Despite these options, treatment decisions can remain complex due to considerations around tolerability, patient characteristics, and clinical outcomes.8,11,15
Research continues to explore resistance mechanisms in ovarian cancer. While treatment options for platinum-resistant ovarian cancer have evolved in recent years, clinical outcomes remain challenging. Ongoing investigation aims to further characterize tumor biology and identify additional approaches to management.16
PROC, platinum-resistant ovarian cancer.
1. NIH National Cancer Institute. Cancer Stat Facts: Ovarian Cancer. Surveillance, Epidemiology, and End Results Program. 2025. Accessed June 18, 2025. https://seer.cancer.gov/statfacts/html/ovary.html 2. Arter ZL, Desmond D, Berenberg JL, Killeen JL, Bunch K, Merritt MA. Epithelial ovarian cancer survival by race and ethnicity in an equal-access healthcare population. Br J Cancer. 2024;130(1):108-113. doi:10.1038/s41416-023-02471-z 3. Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280-304. doi:10.3322/caac.21559 4. Ghirardi V, Fagotti A, Ansaloni L, et al. Diagnostic and therapeutic pathway of advanced ovarian cancer with peritoneal metastases. Cancers (Basel). 2023;15(2):407. doi:10.3390/cancers15020407 5. Chan JK, Tian C, Kesterson JP, et al. Symptoms of women with high-risk, early-stage ovarian cancer. Obstet Gynecol. 2022;139(2):157-162. doi:10.1097/AOG.0000000000004642 6. Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. Semin Oncol Nurs. 2019;35(2):151-156. doi:10.1016/j.soncn.2019.02.001 7. St Laurent J, Liu JF. Treatment approaches for platinum-resistant ovarian cancer. J Clin Oncol. 2024;42(2):127-133. doi:10.1200/JCO.23.01771 8. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer, v4.2026. April 10, 2026. Accessed May 19, 2026. 9. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, et al. Ovarian cancer, version 2.2020. J Natl Compr Canc Netw. 2021;19(2):191-226. doi:10.6004/jnccn.2021.0007 10. Lui JF. Symptoms of women with high-risk early-stage ovarian cancer. Abstract presented at: NCCN 2023 Annual Conference; May 2023; Oxford, UK. 11. Matulonis UA, Lorusso D, Oaknin A, et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study. J Clin Oncol. 2023;41(13):2436-2445. doi:10.1200/JCO.22.01900 12. Eskander RN, Moore KN, Monk BJ, et al. Overcoming the challenges of drug development in platinum-resistant ovarian cancer. Front Oncol. 2023;13:1258228. doi:10.3389/fonc.2023.1258228 13. Richardson DL, Eskander RN, O’Malley DM. Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: a narrative review. JAMA Oncol. 2023;9(6):851-859. doi:10.1001/jamaoncol.2023.0197 14. FDA approves mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. FDA. March 22, 2024. Accessed December 11, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-mirvetuximab-soravtansine-gynx-fra-positive-platinum-resistant-epithelial-ovarian 15. Osman MA, Elkady MS, Nasr KE. Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clin Med Insights Oncol. 2016;10:35-41. doi:10.4137/CMO.S38204 16. Colombo N, Van Gorp T, Matulonis UA, et al. J Clin Oncol. 2023;41(30):4779-4789. doi:10.1200/JCO.22.02624
